Chronic Hepatitis D

This is Hepatitis D that lasts for six months or longer. It happens when someone with Hepatitis D also has Hepatitis B. Like Hepatitis C, it can cause long-term liver damage if not treated.

Condition

What people with Chronic Hepatitis D report

Every report comes from a Lived member, sent anonymously.

Have you tried Hepcludex (Bulevirtide) for Chronic Hepatitis D?

NameHow it went

About Chronic Hepatitis D

What It Is

Chronic hepatitis D is a long-lasting liver infection caused by the hepatitis D virus, also called the delta virus. This virus is incomplete on its own: it can only infect someone who also has hepatitis B, because it borrows part of the hepatitis B virus to enter liver cells. Chronic hepatitis D therefore always means living with two infections at once. It is considered the most severe form of chronic viral hepatitis. Compared with hepatitis B alone, the combination damages the liver faster and more often leads to cirrhosis (heavy scarring of the liver), liver failure and liver cancer. Many people feel well for years, so the infection can go unnoticed until the liver is already scarred. Hepatitis D is uncommon in the United States, but it is more common in parts of Eastern and Southern Europe, the Mediterranean and Middle East, Asia, Africa and South America.

Causes & Risk Factors

Hepatitis D spreads the same way hepatitis B does, through contact with an infected person's blood or other body fluids. That can happen by sharing needles or other drug-injection equipment, through sex without a condom, from a needlestick, or by sharing razors, toothbrushes or nail clippers. It is not spread by coughing, hugging, sharing food or utensils, or casual contact, and it rarely passes from mother to baby at birth. How someone acquires the virus shapes whether it becomes chronic. When hepatitis B and D are caught at the same time, most adults clear both. When hepatitis D is caught by someone who already has hepatitis B, up to 9 in 10 adults develop a chronic infection. The risk is higher for people who have hepatitis B, were born in or lived in a region where hepatitis D is common, have injected drugs, have HIV, or have had sex with someone with hepatitis D. Because hepatitis D cannot exist without hepatitis B, the hepatitis B vaccine also protects against hepatitis D.

How It's Diagnosed

Hepatitis D is diagnosed with blood tests in people who already test positive for hepatitis B. The first test looks for antibodies to the hepatitis D virus, which show that a person has been infected at some point. If antibodies are found, a second test measures hepatitis D RNA (the virus's genetic material). Detectable RNA means the infection is active now, while antibodies without RNA usually mean a past infection that has cleared. Many people with hepatitis B have never been tested for hepatitis D. European and World Health Organization guidelines advise testing everyone with hepatitis B, while current US guidance focuses on people with risk factors, so it is reasonable to ask whether you have been tested. Once the infection is confirmed, further tests show how much the liver has been affected. These include liver blood tests, elastography (a painless ultrasound-based scan that measures liver stiffness, a sign of scarring), and sometimes other imaging or, less often, a liver biopsy. These results guide treatment choices and how closely the liver needs to be watched.

Treatment Options

Treatment aims to suppress the hepatitis D virus, calm liver inflammation and slow the progression toward cirrhosis. A hepatitis specialist usually manages it, and hepatitis B is treated alongside it when needed. The standard hepatitis B antiviral pills do not suppress hepatitis D on their own, which is why separate treatment is considered. In 2026 the FDA approved bulevirtide (Hepcludex), the first medicine made specifically for hepatitis D, for adults whose liver has no cirrhosis or only compensated cirrhosis (scarring without signs of liver failure). It blocks the virus from entering liver cells and is given as a daily injection under the skin, usually self-administered after training. In the main trial, about half of people had a large drop in virus levels together with normal liver enzyme levels after 48 weeks, compared with 2% of untreated people. The approval is based on those lab measures; whether it prevents cirrhosis, cancer or death is still being studied. Treatment is long-term, and stopping it can set off a severe flare of hepatitis, especially with cirrhosis, so it should only be stopped with the care team's plan and follow-up blood tests. Common side effects include injection-site reactions, headache, tiredness and itching. Pegylated interferon alfa, a weekly injection that stimulates the immune system, was the main option before bulevirtide and is still used off-label, usually for 48 weeks. Only a minority of people keep the virus suppressed after it ends, and it often causes flu-like symptoms, fatigue and mood changes, including depression. It is not used in people with advanced, decompensated cirrhosis. For liver failure or liver cancer, a liver transplant can be an option, and medicines given afterward prevent hepatitis B, and therefore hepatitis D, from returning in the new liver.

What to Expect

Chronic hepatitis D is a long-term condition. Without effective control, it can lead to cirrhosis within years rather than decades in many people, although the pace varies widely. Most people have few or no symptoms until the liver is significantly scarred, so how you feel is not a reliable guide to how the liver is doing. Regular follow-up with a liver specialist is central to living with it. Expect periodic blood tests for virus levels and liver function, liver stiffness scans, and, for many people, regular ultrasound or other imaging to look for liver cancer early, when it is most treatable. On treatment, these tests show whether the medicine is working and guide decisions about continuing it. Daily habits matter too. Avoiding alcohol, and checking with the care team before starting new medicines or supplements, some of which can harm the liver, help protect it. Household members and sex partners should be tested for hepatitis B and vaccinated if they are not immune, which protects them from hepatitis D as well. People with hepatitis D should not donate blood, organs or tissue.

When to Seek Help

Ask about hepatitis D testing if you have hepatitis B and have never been tested, especially if you were born in or lived in a region where hepatitis D is common. Arrange a review if you have hepatitis D and are not yet seeing a liver specialist. Contact your care team promptly if you notice increasing tiredness, itching, swelling in the legs or ankles, or unexplained weight loss, or if you are on bulevirtide and have missed doses or are thinking of stopping it. Get emergency care right away for vomiting blood, black or tarry stools, new or worsening confusion or drowsiness, sudden or rapidly worsening swelling of the abdomen, or yellowing of the skin or eyes that is new or getting worse quickly.

Questions to Ask Your Doctor

  1. 1.Do my test results show an active hepatitis D infection, and how much scarring does my liver have?
  2. 2.Am I a candidate for bulevirtide or interferon, and what would long-term treatment and monitoring involve?
  3. 3.How will we know whether treatment is working, and what happens if it is not?
  4. 4.How often should I have liver cancer screening and other follow-up tests?
  5. 5.Who in my household or among my partners should be tested or vaccinated for hepatitis B?

Last reviewed • Oct 2026

Educational content, not medical advice.